Research Feed
PROSERA Failed. Drug Works. Doesn't Matter.
PROSERA Phase 3 missed its primary endpoint. Seralutinib improved 6MWD by +28.2m from baseline versus +13.5m for placebo. Hodges-Lehmann treatment effect: +13.3 meters. P-value: 0.0320. Prespecified threshold: 0.025. Trial failed. The miss triggers hierarchical testing failure — none of the four key
Gossamer Bio: The PROSERA Binary Is Days Away — What the Numbers Actually Say
Gossamer Bio ($2.33, ~$500M market cap) is approaching its defining moment: PROSERA Phase 3 topline data for seralutinib in pulmonary arterial hypertension, expected in February 2026. The stock is a pure binary. Options are pricing 548% implied volatility — the market knows this is all-or-nothing. A